natura-alpha (TAK-114) - Natrogen Therapeutics, Takeda
Takeda: Q3 FY 2015 Results (Takeda) - Feb 4, 2016 - Discontinued in ulcerative colitis due to potential for a better product profile with a similar candidate compound 
Discontinued • Immunology • Inflammatory Bowel Disease
http://www.takeda.com/investor-information/files/qr2015_q3_f_en.pdf
 
Feb 4, 2016
 
.